OF
Oaktree Fund Advisors, LLC
13F filer · CIK 0001822973Reported Aug 14, 2026
13F portfolio value$57.8MU.S. long equity reported on 13F
Positions13Not reported new · Not reported closed
Net flow last quarterNot reportedBuys minus sells
Top 10 positions weight95.7%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202613 positions | |||||
| $13.6M | 23.59% | 0.03% | +9.9% | Q2 2021 | |
| $8.91M | 15.41% | 0.01% | +36.1% | Q2 2025 | |
| $6.84M | 11.83% | 0.01% | +9.9% | Q2 2021 | |
| $5.77M | 9.98% | 0.03% | +16.8% | Q1 2023 | |
| $5.18M | 8.96% | 0.01% | +9.9% | Q3 2021 | |
| $4.05M | 7.00% | 0.02% | Not reported | Q2 2025 | |
| $3.6M | 6.23% | Not reported | New | Q2 2026 | |
| $3.57M | 6.17% | Not reported | +9.9% | Q3 2024 | |
| $1.97M | 3.41% | 0.00% | +10.0% | Q1 2026 | |
| $1.81M | 3.13% | 0.96% | New | Q2 2026 | |
| $1.79M | 3.09% | 0.00% | +9.7% | Q2 2022 | |
| BTBTAIBioXcel Therapeutics, Inc. | $346K | 0.60% | 0.78% | +472.3% | Q2 2025 |
| $281K | 0.49% | 0.02% | -65.1% | Q2 2022 | |
| Q1 2026Reported May 20, 202612 positions | |||||
| $14.9M | 26.23% | 0.03% | -5.6% | Q2 2021 | |
| $7.99M | 14.04% | 0.01% | Not reported | Q2 2021 | |
| $7.27M | 12.77% | 0.01% | -1.8% | Q2 2025 | |
| $6.38M | 11.21% | 0.01% | -1.8% | Q2 2021 | |
| $5.02M | 8.82% | 0.03% | Not reported | Q1 2023 | |
| $4.41M | 7.74% | 0.01% | -1.8% | Q3 2021 | |
| $3.8M | 6.67% | Not reported | +6.7% | Q3 2024 | |
| $3.15M | 5.53% | 0.00% | -1.8% | Q4 2023 | |
| $1.66M | 2.92% | 0.00% | New | Q1 2026 | |
| $1.53M | 2.69% | 0.00% | -1.8% | Q2 2022 | |
| $264K | 0.46% | 0.07% | +48.2% | Q2 2022 | |
| BTBTAIBioXcel Therapeutics, Inc. | $57.5K | 0.10% | 0.16% | Not reported | Q2 2025 |
| Q4 2025Reported Feb 17, 202614 positions | |||||
| $13.9M | 25.64% | 0.03% | -16.7% | Q2 2021 | |
| $7.9M | 14.63% | 0.01% | -5.2% | Q2 2025 | |
| $5.56M | 10.28% | 0.01% | +0.1% | Q2 2021 | |
| $4.71M | 8.71% | 0.00% | -5.2% | Q4 2023 | |
| $4.07M | 7.52% | Not reported | +2.4% | Q3 2025 | |
| $3.88M | 7.18% | 0.01% | -5.2% | Q3 2021 | |
| $3.29M | 6.09% | Not reported | -5.2% | Q1 2025 | |
| $3.06M | 5.67% | Not reported | +60.0% | Q3 2024 | |
| $2.24M | 4.15% | Not reported | -5.2% | Q2 2025 | |
| $1.81M | 3.35% | 0.09% | -5.1% | Q3 2024 | |
| $1.49M | 2.75% | 0.00% | -24.5% | Q2 2022 | |
| $1.09M | 2.01% | 0.00% | Not reported | Q2 2023 | |
| $397K | 0.73% | 0.05% | +93.2% | Q2 2022 | |
| BTBTAIBioXcel Therapeutics, Inc. | $68.7K | 0.13% | 0.19% | Not reported | Q2 2025 |
| Q3 2025Reported Nov 14, 202515 positions | |||||
| $13.7M | 25.26% | 0.04% | -24.1% | Q2 2021 | |
| $6.27M | 11.55% | 0.01% | Not reported | Q2 2025 | |
| $5.52M | 10.17% | 0.01% | +14.6% | Q2 2021 | |
| $4.64M | 8.55% | 0.00% | Not reported | Q4 2023 | |
| $4.19M | 7.71% | Not reported | Not reported | Q1 2025 | |
| $3.8M | 7.00% | Not reported | New | Q3 2025 | |
| $3.16M | 5.82% | 0.01% | -30.1% | Q3 2021 | |
| $2.86M | 5.27% | Not reported | +104.4% | Q2 2025 | |
| $2.2M | 4.05% | Not reported | Not reported | Q3 2024 | |
| $2.19M | 4.03% | 0.09% | Not reported | Q3 2024 | |
| $1.79M | 3.30% | 0.00% | Not reported | Q2 2022 | |
| $1.46M | 2.68% | 0.00% | +60.4% | Q2 2025 | |
| $1.32M | 2.43% | Not reported | New | Q3 2025 | |
| $623K | 1.15% | 0.03% | Not reported | Q2 2022 | |
| BTBTAIBioXcel Therapeutics, Inc. | $110K | 0.20% | 0.21% | Not reported | Q2 2025 |
Premium opens every quarter this fund has filed